Immatics
has the potential to reach a large patient population so | Immatics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
37 of 75
Related slides by other companies
Neumora Therapeutics
IPO
September 2023
phase efficacy population patient demographics and characteristics similar across treatment groups | Neumora Therapeutics
Immix Biopharma
Investor Presentation
March 2024
sizable relapsed refractory amyloidosis patient population immix | Immix Biopharma
Ocuphire Pharma
Results
June 2021
patient population subject disposition | Ocuphire Pharma
Dynacure
IPO
July 2021
our population is of patients in the | Dynacure
Other recent decks by Immatics
See all presentations (2 decks)
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights